Intratumoral pseudoaneurysm within a liver metastasis of gastric cancer: a case report

Abstract

Background: Intrahepatic artery pseudoaneurysms are mostly iatrogenic and result from hepatobiliary interventions. The incidence of intrahepatic artery pseudoaneurysms within liver tumors without prior intervention is extremely rare. We presented herein the first report of a case of an intratumoral pseudoaneurysm within a liver metastasis of gastric cancer without any prior intervention during chemotherapy. Case presentation: A 59-year-old male patient underwent a distal gastrectomy and D2 lymph node dissection for gastric cancer. He was treated in the emergency room for right abdominal pain following the 4th cycle of nivolumab administration as second-line chemotherapy after adjuvant chemotherapy with S-1 and first-line chemotherapy for a liver metastasis of gastric cancer with ramucirumab plus paclitaxel. CT showed a 72-mm metastatic liver tumor containing a 9-mm pseudoaneurysm and fluid collection around the hepatic edge. Intrahepatic artery pseudoaneurysm within the metastatic liver tumor was diagnosed, with the surrounding fluid indicating potential, active bleeding. An emergency angiography confirmed the presence of a pseudoaneurysm in the intrahepatic artery, which was embolized using microcoils. The contributory causes of the intratumoral pseudoaneurysm were assumed to be the following: (1) tumor necrosis leading to encasement, erosion of the vessel wall, and subsequent arterial wall weakening; and (2) inhibition of vascular endothelial growth by ramucirumab resulting in a vessel wall breach and pseudoaneurysm formation. Conclusion: It is necessary to recognize that pseudoaneurysms can arise within a metastatic liver tumor during chemotherapy.

CBX2 depletion inhibits the proliferation, invasion and migration of gastric cancer cells by inactivating the YAP/β-catenin pathway

“…it is estimated that >1,000,000 new cases of Gc were diagnosed (5.7% of the overall cancer incidence) and 800,000 deaths occurred (8.2% of all cancer mortalities) in 2018 worldwide (3). Furthermore, according to previous studies, patients with Gc regularly exhibit partial metastasis at diagnosis or during chemotherapy (4,5). despite advances in Gc diagnostic techniques, surgery and neoadjuvant chemoradiotherapy, the 5-year survival rate remains poor in china, particularly at advanced stages (6,7).…”